Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-19T01:49:17.492Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson’s disease rat model

Published online by Cambridge University Press:  24 September 2020

Iman Fatemi Open the ORCID record for Iman Fatemi [Opens in a new window] ,
Abbas Abdollahi ,
Ali Shamsizadeh ,
Mohammad Allahtavakoli  and
Ali Roohbakhsh
Iman Fatemi
Affiliation:
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
Abbas Abdollahi
Affiliation:
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Ali Shamsizadeh
Affiliation:
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Mohammad Allahtavakoli
Affiliation:
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Ali Roohbakhsh*
Affiliation:
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
*
Author for correspondence: Ali Roohbakhsh, Email: roohbakhsha@mums.ac.ir
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

G protein-coupled receptor 55 (GPR55) is an orphan G protein-coupled receptor with various physiological functions. Recent evidence suggests that this receptor may be involved in the control of motor functions. Therefore, in the present study, we evaluated the effects of intra-striatal administration of GPR55 selective ligands in a rat model of Parkinson’s disease.

Methods:

Experimental Parkinson was induced by unilateral intra-striatal administration of 6-hydroxydopamine (6-OHDA, 10 µg/rat). L-α-lysophosphatidylinositol (LPI, 1 and 5 µg/rat), an endogenous GPR55 agonist, and ML193 (1 and 5 µg/rat), a selective GPR55 antagonist, were injected into the striatum of 6-OHDA-lesioned rats. Motor performance and balance skills were evaluated using the accelerating rotating rod and the ledged beam tests. The sensorimotor function of the forelimbs and locomotor activity were assessed by the adhesive removal and open field tests, respectively.

Results:

6-OHDA-lesioned rats had impaired behaviours in all tests. Intra-striatal administration of LPI in 6-OHDA-lesioned rats increased time on the rotarod, decreased latency to remove the label, with no significant effect on slip steps, and locomotor activity. Intra-striatal administration of ML193 also increased time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats mostly at the dose of 1 µg/rat.

Conclusions:

This study suggests that the striatal GPR55 is involved in the control of motor functions. However, considering the similar effects of GPR55 agonist and antagonist, it may be concluded that this receptor has a modulatory role in the control of motor deficits in an experimental model of Parkinson.

Keywords

Parkinson’s disease6-hydroxydopamineGPR55striatummovement
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 33 , Issue 1 , February 2021 , pp. 15 - 21
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Al Suleimani, YM, Al Mahruqi, AS and Hiley, CR (2015) Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery. European Journal of Pharmacology 765, 107–114.CrossRefGoogle ScholarPubMed
Alavi, MS, Hosseinzadeh, H, Shamsizadeh, A and Roohbakhsh, A (2016) The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence. Pharmacological Reports 683, 592–597.CrossRefGoogle Scholar
Balestrino, R and Schapira, AHV (2020) Parkinson disease. European Journal of Neurology 27, 27–42.CrossRefGoogle ScholarPubMed
Basavarajappa, BS, Shivakumar, M, Joshi, V and Subbanna, S (2017) Endocannabinoid system in neurodegenerative disorders. Journal of Neurochemistry 1425, 624–648.CrossRefGoogle Scholar
Bishop, C, Kamdar, DP and Walker, PD (2003) Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. Synapse 502, 164–170.CrossRefGoogle Scholar
Brotchie, JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders 208, 919–931.CrossRefGoogle Scholar
Celorrio, M, Fernandez-Suarez, D, Rojo-Bustamante, E, Echeverry-Alzate, V, Ramirez, MJ, Hillard, CJ, Lopez-Moreno, JA, Maldonado, R, Oyarzabal, J, Franco, R and Aymerich, MS (2016) Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease. Brain, Behavior, and Immunity 57, 94–105.CrossRefGoogle ScholarPubMed
Celorrio, M, Rojo-Bustamante, E, Fernandez-Suarez, D, Saez, E, Estella-Hermoso de Mendoza, A, Muller, CE, Ramirez, MJ, Oyarzabal, J, Franco, R and Aymerich, MS (2017) GPR55: A therapeutic target for Parkinson’s disease? Neuropharmacology 125, 319–332.CrossRefGoogle ScholarPubMed
Chung, SJ, Yoo, HS, Lee, HS, Oh, JS, Kim, JS, Sohn, YH and Lee, PH (2018) The pattern of striatal dopamine depletion as a prognostic marker in de novo Parkinson disease. Clinical Nuclear Medicine 4311, 787–792.CrossRefGoogle Scholar
De Petrocellis, L and Di Marzo, V (2010) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: Focus on G-protein-coupled receptors and transient receptor potential channels. Journal of Neuroimmune Pharmacology 51, 103–121.CrossRefGoogle Scholar
Deliu, E, Sperow, M, Console-Bram, L, Carter, RL, Tilley, DG, Kalamarides, DJ, Kirby, LG, Brailoiu, GC, Brailoiu, E, Benamar, K and Abood, ME (2015) The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray. Molecular Pharmacology 882, 265–272.CrossRefGoogle Scholar
Fatemi, I, Shamsizadeh, A, Roohbakhsh, A, Ayoobi, F, Sanati, MH and Motevalian, M (2016) Increase in mRNA level of orexin1 and 2 receptors following induction of experimental autoimmune encephalomyelitis in mice. Iranian Journal of Allergy, Asthma, and Immunology 151, 20–26.Google Scholar
Fino, E, Glowinski, J and Venance, L (2005) Bidirectional activity-dependent plasticity at corticostriatal synapses. Journal of Neuroscience 2549, 11279–11287.CrossRefGoogle Scholar
Gilgun-Sherki, Y, Melamed, E, Mechoulam, R and Offen, D (2003) The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & Toxicology 932, 66–70.CrossRefGoogle Scholar
Gonzalez, S, Scorticati, C, Garcia-Arencibia, M, de Miguel, R, Ramos, JA and Fernandez-Ruiz, J (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Research 1073–1074, 209–219.CrossRefGoogle Scholar
Hadadianpour, Z, Fatehi, F, Ayoobi, F, Kaeidi, A, Shamsizadeh, A and Fatemi, I (2017) The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson’s disease. Neurological Research 399, 845–851.CrossRefGoogle Scholar
Haddad, F, Sawalha, M, Khawaja, Y, Najjar, A and Karaman, R (2017) Dopamine and levodopa prodrugs for the treatment of parkinson’s disease. Molecules 23(1), 40.CrossRefGoogle ScholarPubMed
Hakimizadeh, E, Shamsizadeh, A, Roohbakhsh, A, Arababadi, MK, Hajizadeh, MR, Shariati, M, Fatemi, I, Moghadam-Ahmadi, A, Bazmandegan, G, Rezazadeh, H and Allahtakoli, M (2017a) TRPV1 receptor-mediated expression of Toll-like receptors 2 and 4 following permanent middle cerebral artery occlusion in rats. Iranian Journal of Basic Medical Sciences 208, 863–869.Google Scholar
Hakimizadeh, E, Shamsizadeh, A, Roohbakhsh, A, Arababadi, MK, Hajizadeh, MR, Shariati, M, Rahmani, MR and Allahtavakoli, M (2017b) Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model. Fundamental & Clinical Pharmacology 314, 420–428.CrossRefGoogle Scholar
Henstridge, CM (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 893-4, 179–187.CrossRefGoogle ScholarPubMed
Henstridge, CM, Balenga, NA, Schroder, R, Kargl, JK, Platzer, W, Martini, L, Arthur, S, Penman, J, Whistler, JL, Kostenis, E, Waldhoer, M and Irving, AJ (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology 1603, 604–614.CrossRefGoogle Scholar
Hill, JD, Zuluaga-Ramirez, V, Gajghate, S, Winfield, M and Persidsky, Y (2018) Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. British Journal of Pharmacology 17516, 3407–3421.CrossRefGoogle Scholar
Hurst, K, Badgley, C, Ellsworth, T, Bell, S, Friend, L, Prince, B, Welch, J, Cowan, Z, Williamson, R, Lyon, C, Anderson, B, Poole, B, Christensen, M, McNeil, M, Call, J and Edwards, JG (2017) A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity. Hippocampus 279, 985–998.CrossRefGoogle Scholar
Kallendrusch, S, Kremzow, S, Nowicki, M, Grabiec, U, Winkelmann, R, Benz, A, Kraft, R, Bechmann, I, Dehghani, F and Koch, M (2013) The G protein-coupled receptor 55 ligand l-alpha-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia 6111, 1822–1831.CrossRefGoogle Scholar
Kaplan, JS, Stella, N, Catterall, WA and Westenbroek, RE (2017) Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America 114, 11229–11234.CrossRefGoogle Scholar
Kapur, A, Zhao, P, Sharir, H, Bai, Y, Caron, MG, Barak, LS and Abood, ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. Journal of Biological Chemistry 28443, 29817–29827.CrossRefGoogle Scholar
Kargl, J, Balenga, N, Parzmair, GP, Brown, AJ, Heinemann, A and Waldhoer, M (2012) The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. Journal of Biological Chemistry 28753, 44234–44248.CrossRefGoogle Scholar
Khan, MM, Ahmad, A, Ishrat, T, Khan, MB, Hoda, MN, Khuwaja, G, Raza, SS, Khan, A, Javed, H, Vaibhav, K and Islam, F (2010) Resveratrol attenuates 6-hydroxy-dopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Research 1328, 139–151.CrossRefGoogle Scholar
Kramar, C, Loureiro, M, Renard, J and Laviolette, SR (2017) Palmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing. Cannabis Cannabinoid Research 21, 8–20.CrossRefGoogle Scholar
Kravitz, AV, Tye, LD and Kreitzer, AC (2012) Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nature Neuroscience 156, 816–818.CrossRefGoogle Scholar
Liu, B, Song, S, Jones, PM and Persaud, SJ (2015) GPR55: From orphan to metabolic regulator? Pharmacology & Therapeutics 145, 35–42.CrossRefGoogle ScholarPubMed
Marichal-Cancino, BA, Fajardo-Valdez, A, Ruiz-Contreras, AE, Mendez-Diaz, M and Prospero-Garcia, O (2017) Advances in the physiology of gpr55 in the central nervous system. Current Neuropharmacology 155, 771–778.Google Scholar
Marichal-Cancino, BA, Fajardo-Valdez, A, Ruiz-Contreras, AE, Mendez-Diaz, M and Prospero-Garcia, O (2018) Possible role of hippocampal GPR55 in spatial learning and memory in rats. Acta Neurobiologiae Experimentalis 781, 41–50.CrossRefGoogle Scholar
Marichal-Cancino, BA, Sanchez-Fuentes, A, Mendez-Diaz, M, Ruiz-Contreras, AE and Prospero-Garcia, O (2016) Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm. Behavioural Pharmacology 274, 393–396.CrossRefGoogle Scholar
Martinez-Pinilla, E, Reyes-Resina, I, Onatibia-Astibia, A, Zamarbide, M, Ricobaraza, A, Navarro, G, Moreno, E, Dopeso-Reyes, IG, Sierra, S, Rico, AJ et al. (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Experimental Neurology 261, 44–52.CrossRefGoogle ScholarPubMed
Meadows, A, Lee, JH, Wu, CS, Wei, Q, Pradhan, G, Yafi, M, Lu, HC and Sun, Y (2016) Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. International Journal of Obesity 403, 417–424.CrossRefGoogle Scholar
Moghaddam, HF, Khodayar, MJ, Abarghouei, SM and Ardestani, MS (2010) Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine. Saudi Pharmaceutical Journal 184, 207–215.CrossRefGoogle Scholar
Morales, P and Reggio, PH (2017) An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. Cannabis Cannabinoid Research 21, 265–273.CrossRefGoogle Scholar
More, SV and Choi, DK (2015) Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Molecular Neurodegeneration 10, 17.CrossRefGoogle ScholarPubMed
O’Connor, KA, Feustel, PJ, Ramirez-Zamora, A, Molho, E, Pilitsis, JG and Shin, DS (2016) Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats. Behavioural Brain Research 301, 226–237.CrossRefGoogle ScholarPubMed
Papa, SM (2008) The cannabinoid system in Parkinson’s disease: Multiple targets to motor effects. Experimental Neurology 2112, 334–338.CrossRefGoogle Scholar
Paxinos, G and Watson, C (2007) The Rat Brain in Stereotaxic Coordinates. Amsterdam: Academic Press.Google Scholar
Pertwee, RG, Howlett, AC, Abood, ME, Alexander, SP, Di Marzo, V, Elphick, MR, Greasley, PJ, Hansen, HS, Kunos, G, Mackie, K et al. (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacological Review 624, 588–631.CrossRefGoogle Scholar
Prakash, A, Chopra, K and Medhi, B (2013) Granulocyte-colony stimulating factor improves Parkinson’s disease associated with co-morbid depression: An experimental exploratory study. Indian Journal of Pharmacology 456, 612–615.Google Scholar
Rahimi, A, Hajizadeh Moghaddam, A and Roohbakhsh, A (2015) Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats. Fundamental & Clinical Pharmacology 292, 185–190.CrossRefGoogle Scholar
Rauch, F, Schwabe, K and Krauss, JK (2010) Effect of deep brain stimulation in the pedunculopontine nucleus on motor function in the rat 6-hydroxydopamine Parkinson model. Behavioural Brain Research 2101, 46–53.CrossRefGoogle Scholar
Rutten, S, Vriend, C, van der Werf, YD, Berendse, HW, Weintraub, D and van den Heuvel, OA (2017) The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naive Parkinson’s disease. Parkinsonism & Related Disorders 39, 31–36.CrossRefGoogle ScholarPubMed
Ryberg, E, Larsson, N, Sjogren, S, Hjorth, S, Hermansson, NO, Leonova, J, Elebring, T, Nilsson, K, Drmota, T and Greasley, PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 1527, 1092–1101.CrossRefGoogle Scholar
Ryman, SG and Poston, KL (2019) MRI biomarkers of motor and non-motor symptoms in Parkinson’s disease. Parkinsonism & Related Disorders 73, 85–93.CrossRefGoogle ScholarPubMed
Sedaghat, R, Roghani, M and Khalili, M (2014) Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-induced hemi-parkinsonian rat model. Iranian Journal of Pharmaceutical Research 131, 227–234.Google Scholar
Sharir, H, Console-Bram, L, Mundy, C, Popoff, SN, Kapur, A and Abood, ME (2012) The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. Journal of Neuroimmune Pharmacology 74, 856–865.CrossRefGoogle Scholar
Singh, NS, Bernier, M and Wainer, IW (2016) Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacological Research 111, 757–766.CrossRefGoogle ScholarPubMed
Tuduri, E, Imbernon, M, Hernandez-Bautista, RJ, Tojo, M, Ferno, J, Dieguez, C and Nogueiras, R (2017) GPR55: A new promising target for metabolism? Journal of Molecular Endocrinology 583, R191–R202.CrossRefGoogle Scholar
Voronin, MV, Kadnikov, IA, Voronkov, DN and Seredenin, SB (2019) Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease. Scientific Reports 91, 17020.CrossRefGoogle Scholar
Wagner, MJ, Kim, TH, Savall, J, Schnitzer, MJ and Luo, L (2017) Cerebellar granule cells encode the expectation of reward. Nature 5447648, 96–100.CrossRefGoogle Scholar
Wang, XF, Galaj, E, Bi, GH, Zhang, C, He, Y, Zhan, J, Bauman, M, Gardner, EL and Xi, ZX (2020) Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1/CB2 versus GPR55 receptors. British Journal of Pharmacology 177, 1865–1880.CrossRefGoogle Scholar
Wu, C-S, Chen, H, Sun, H, Zhu, J, Jew, CP, Wager-Miller, J, Straiker, A, Spencer, C, Bradshaw, H and Mackie, K (2013) GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS One 84, e60314.CrossRefGoogle Scholar